Lenz Therapeutics News and Activities
Presence
Lenz Therapeutics develops eye medicines for vision conditions. Its products and research services focus on prescription eye drops for adults with presbyopia and related eye care needs.
Lenz Therapeutics products and services overview:
- Eye medicines
- Prescription eye drops
- Vision care therapies
- Ophthalmic research
Revenue: ~$0 million
Employees: 60
Headquarters: San Diego, United States (USA)
Lenz Therapeutics is one of the...
Lenz Therapeutics is a company listed under the stock ticker LENZ (US).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Lenz Therapeutics
- Eef Schimmelpennink, President and Chief Executive Officer
- James Mccollum, Director
- Jeff George, Director
Create your alert
to follow the executive moves at Lenz Therapeutics.
Biotechnology
Lenz Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Lenz Therapeutics
- LENZ Therapeutics to Participate in Upcoming Investor Conferences
- Press Releases
- LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
- LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
- LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
- LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
- LENZ Therapeutics to Present at Upcoming Investor Conferences
- LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
- View more press releases Close
Social media about Lenz Therapeutics
- Lenz Therapeutics on Wikipedia, Google News & Yahoo Finance
- Lenz Therapeutics on LinkedIn, X (Twitter) & YouTube
